Drug · CHEMBL556
DEFEROXAMINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DEFEROXAMINE. Drugs and targets, record CHEMBL556. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL556
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Deferoxamina, Desferoxamine b, Desferrioxamine, Desferrioxamine b, Dfo-b, NSC-527604
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases19
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 19Source Open Targets
See all 19 diseasesTrials50
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04633889 | Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury | Phase 2 | 320 | 2026-01-26 | deferoxamine | Its name | ClinicalTrials.gov |
| NCT02041299 | Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias | Phase 4 | 230 | 2021-08-10 | deferoxamine | Its name | ClinicalTrials.gov |
| NCT00600938 | Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload | Phase 2 | 197 | 2014-08-27 | deferoxamine | Its name | ClinicalTrials.gov |
| NCT01254227 | Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload | Phase 2 | 60 | 2021-06-24 | deferoxamine | Its name | ClinicalTrials.gov |
| NCT01662895 | High-Dose Deferoxamine in Intracerebral Hemorrhage | Phase 2 | 42 | 2019-05-30 | deferoxamine | Its name | ClinicalTrials.gov |
| NCT01459718 | Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload | Phase 2 | 32 | 2019-10-23 | deferoxamine | Its name | ClinicalTrials.gov |
| NCT00901199 | Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload | Phase 2 | 22 | 2021-08-12 | deferoxamine | Its name | ClinicalTrials.gov |
| NCT00115349 | Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases | Phase 2 | 20 | 2014-01-14 | deferoxamine | Its name | ClinicalTrials.gov |
| NCT00749515 | Pilot Study for Patients With Poor Response to Deferasirox | Phase 4 | 15 | 2019-02-06 | deferoxamine | Its name | ClinicalTrials.gov |
| NCT00658411 | Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation | 5 | 2013-04-09 | deferoxamine | Its name | ClinicalTrials.gov |
1 to 10 of 50
See all 50 trialsComparisons in its trials24
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Deferoxamine vs Placebo: Acute Kidney Injury | 99 of 151 | 108 of 150 | 301 | NCT04633889 | Trial comparisons |
| Deferoxamine vs Placebo: Number of Participants With Prolonged Mechanical Ventilation | 31 of 151 | 27 of 150 | 301 | NCT04633889 | Trial comparisons |
| Deferoxamine vs Placebo: Number of Participants With Sepsis | 6 of 151 | 2 of 150 | 301 | NCT04633889 | Trial comparisons |
| Deferoxamine vs Placebo: Number of Participants With Postoperative Myocardial Injury | 15 of 151 | 15 of 150 | 301 | NCT04633889 | Trial comparisons |
| Deferoxamine vs Placebo: deaths from any cause | 6 of 151 | 6 of 150 | 301 | NCT04633889 | Trial comparisons |
| Deferoxamine vs Placebo: Number of Participants With Major Adverse Kidney Events | 14 of 151 | 13 of 150 | 301 | NCT04633889 | Trial comparisons |
| Deferoxamine vs Placebo: serious adverse events | 23 of 151 | 25 of 150 | 301 | NCT04633889 | Trial comparisons |
| Deferiprone vs Deferoxamine: deaths from any cause | 1 of 152 | 1 of 76 | 228 | NCT02041299 | Trial comparisons |
| Deferiprone vs Deferoxamine: serious adverse events | 40 of 152 | 14 of 76 | 228 | NCT02041299 | Trial comparisons |
Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL vs Core; Deferoxamine (DFO). For Extension Labeled as DFO to DFO: Core Study: Cardiac Function and the Proportion of Patients Dropping Out Due to Cardiac Dysfunction After Treatment With Deferasirox vs. Deferoxamine | 3 of 98 | 2 of 99 | 197 | NCT00600938 | Trial comparisons |
1 to 10 of 24
See all 24 comparisons in its trialsPapers from its trials46
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL556
GET https://conductscience.org/api/drugs/v1/CHEMBL556/trials?page=2